Stanford Medicine researchers create virtual biotech company using 37,000 AI agents
Researchers at Stanford Medicine have developed a simulated biotechnology company utilizing approximately 37,000 artificial intelligence agents. The study, published in the journal Science, established an AI-driven scientific director program to oversee groups tasked with identifying drug targets and planning human clinical trials.
Using these AI agents, the researchers cataloged roughly 50,000 clinical trials in less than a week. The system analyzed molecular measurements and evaluated drug specificity for particular cell types. A key finding was that drugs targeting genes with a 'switch-like' bimodal function showed significantly improved outcomes. Specifically, these drugs were 40% more likely to progress from Phase 1 to Phase 2 trials and 48% more likely to reach the market. Additionally, they exhibited 32% fewer harmful side effects compared to broad-spectrum drugs. This pattern was observed across various conditions, including cancer, brain, heart, kidney, and lung diseases.
Entities
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 4 SOURCES] These drugs showed 32% fewer harmful side effects than broad-spectrum drugs. www.diariodemallorca.es · www.informacion.es · www.farodevigo.es · www.elperiodicoextremadura.com
- [● 4 SOURCES] The AI programs cataloged approximately 50,000 clinical trials in less than one week. www.diariodemallorca.es · www.informacion.es · www.farodevigo.es · www.elperiodicoextremadura.com
- [● 4 SOURCES] Drugs targeting genes with a switch-like function were 40% more likely to pass from Phase 1 to Phase 2 clinical trials. www.diariodemallorca.es · www.informacion.es · www.farodevigo.es · www.elperiodicoextremadura.com
- [● 4 SOURCES] Stanford Medicine researchers created a simulated biotechnology company using approximately 37,000 AI agents. www.diariodemallorca.es · www.informacion.es · www.farodevigo.es · www.elperiodicoextremadura.com